Fosun Pharma Ranked 4th among 2014 China Pharmaceutical Industry Top 100 Enterprises in Terms of Overall Strength
The 2014 China Pharmaceutical Industry Annual Summit recently held in Guangzhou issued the “2014 China Pharmaceutical Industry Top 100 Enterprises”, in which Fosun Pharma ranked 4th among 100 enterprises in terms of overall strength.
Other enterprises made to the list include Yangtze River Pharmaceutical Group, Shanghai Pharma and Harbin Pharmaceutical Group, etc. The event co-sponsored by China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association, China Pharmaceutical Enterprise Promotion and Reed Sinopharm Exhibitions, also issued the “2014 China Pharmaceutical Industry Outstanding Product Brands”.
Pharmaceutical industry is the core of Fosun Pharma’s pharmaceutical business development. For the first three quarters of 2014, Fosun Pharma’s pharmaceutical business growth momentum remained strong. Through many year’s M&A, R&D and market promotion activities, Fosun Pharma has become a market leader with regard to its key products in all of the 5 major medical segments, and has maintained rapid growth in major core product sales. Currently, the Company has 15 products which are capable of generating more than RMB100 million in sales revenue. Fosun Pharma will continue to concentrate superior resources, and put in more efforts to develop its core pharmaceutical business and enhance its industry-wide competitiveness.
Meanwhile, adhering to the brand concept of “Innovation for Good Health”, Fosun Pharma is committed to boosting corporate brand building and strengthening corporate social responsibility, which has significantly augmented the Company’s brand awareness and reputation. The Company now is gaining increasing overall strength year by year and has won praise from all walks of life and industry experts. All of this is bound to lay a solid foundation for the realization of the Company’s vision of “becoming a leading company in global pharmaceutical & health care market”.
It’s reported that 2014 China Pharmaceutical Industry Annual Summit, with the theme of quality, trust and brand, integrating policy interpretation, industry analysis, corporate product brand recommendation and dissemination, industry talks, is designed to promote corporate brand building. Based on the recommendation by industry associations, the list of 2014 China Pharmaceutical Industry Top 100 Enterprises in Terms of Overall Strength is reviewed and determined upon serious discussions by the Recommendation Expert Committee in line with the principle of “objective, scientific and fair”.
Other enterprises made to the list include Yangtze River Pharmaceutical Group, Shanghai Pharma and Harbin Pharmaceutical Group, etc. The event co-sponsored by China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association, China Pharmaceutical Enterprise Promotion and Reed Sinopharm Exhibitions, also issued the “2014 China Pharmaceutical Industry Outstanding Product Brands”.
Pharmaceutical industry is the core of Fosun Pharma’s pharmaceutical business development. For the first three quarters of 2014, Fosun Pharma’s pharmaceutical business growth momentum remained strong. Through many year’s M&A, R&D and market promotion activities, Fosun Pharma has become a market leader with regard to its key products in all of the 5 major medical segments, and has maintained rapid growth in major core product sales. Currently, the Company has 15 products which are capable of generating more than RMB100 million in sales revenue. Fosun Pharma will continue to concentrate superior resources, and put in more efforts to develop its core pharmaceutical business and enhance its industry-wide competitiveness.
Meanwhile, adhering to the brand concept of “Innovation for Good Health”, Fosun Pharma is committed to boosting corporate brand building and strengthening corporate social responsibility, which has significantly augmented the Company’s brand awareness and reputation. The Company now is gaining increasing overall strength year by year and has won praise from all walks of life and industry experts. All of this is bound to lay a solid foundation for the realization of the Company’s vision of “becoming a leading company in global pharmaceutical & health care market”.
It’s reported that 2014 China Pharmaceutical Industry Annual Summit, with the theme of quality, trust and brand, integrating policy interpretation, industry analysis, corporate product brand recommendation and dissemination, industry talks, is designed to promote corporate brand building. Based on the recommendation by industry associations, the list of 2014 China Pharmaceutical Industry Top 100 Enterprises in Terms of Overall Strength is reviewed and determined upon serious discussions by the Recommendation Expert Committee in line with the principle of “objective, scientific and fair”.